Literature DB >> 9760290

S-nitrosoglutathione reduces the rate of embolization in humans.

J Molloy1, J F Martin, P A Baskerville, S C Fraser, H S Markus.   

Abstract

BACKGROUND: Antiplatelet agents presently used in the secondary prevention of cardiovascular disease fail to prevent the majority of cases of recurrent stroke and systemic embolization. An evaluation of the efficacy of new agents is hampered by a lack of in vivo models in humans. Asymptomatic cerebral embolic signals (ES) may be detected with the use of transcranial Doppler ultrasonography. These signals are particularly common after carotid endarterectomy, and this provides a situation in which new antiplatelet agents can be evaluated. With this model, we determined the effectiveness of S-nitrosoglutathione (GSNO), a nitric oxide donor with relative platelet specificity, in reducing cerebral embolization. METHODS AND
RESULTS: Transcranial Doppler ultrasound recordings from the ipsilateral middle cerebral artery were made after carotid endarterectomy in 12 control patients and 12 patients receiving intravenous GSNO from the induction of anesthesia until 2 hours after skin closure. Recording times were 0.5 to 3.5, 6 to 7, and 24 to 25 hours after skin closure. The Doppler signal was recorded onto tape, and analysis for ES was performed, with the investigators blinded to treatment group. All patients received aspirin 300 mg/d before surgery and 5000 IU of heparin during surgery. The median (range) number of ES detected during the initial 3-hour postoperative recording was markedly reduced in the GSNO group compared with the control group: 7.5 (0 to 61) versus 38.5 (1 to 219) (P=0.018). This difference persisted until 6 hours after surgery.
CONCLUSIONS: Despite the administration of aspirin and heparin, frequent embolization occurred and was markedly reduced after the administration of GSNO. This demonstrates the potential use of platelet-specific nitric oxide donors in the treatment of thromboembolic disease. This model of cerebral embolism may allow determination of the effectiveness of new antiplatelet agents in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760290     DOI: 10.1161/01.cir.98.14.1372

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  S-Nitrosoglutathione administration ameliorates cauda equina compression injury in rats.

Authors:  Anandakumar Shunmugavel; Mushfiquddin Khan; Marcus M Martin; Anne G Copay; Brian R Subach; Thomas C Schuler; Inderjit Singh
Journal:  Neurosci Med       Date:  2012-09-25

2.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

4.  The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke.

Authors:  Mushfiquddin Khan; Tajinder S Dhammu; Harutoshi Sakakima; Anadakumar Shunmugavel; Anne G Gilg; Avtar K Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2012-11       Impact factor: 5.372

Review 5.  S-nitrosoglutathione.

Authors:  Katarzyna A Broniowska; Anne R Diers; Neil Hogg
Journal:  Biochim Biophys Acta       Date:  2013-02-14

Review 6.  S-nitrosothiols as selective antithrombotic agents - possible mechanisms.

Authors:  M P Gordge; F Xiao
Journal:  Br J Pharmacol       Date:  2010-03-08       Impact factor: 8.739

7.  Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion.

Authors:  Harutoshi Sakakima; Mushfiquddin Khan; Tajinder S Dhammu; Anandakumar Shunmugavel; Yoshihiro Yoshida; Inderjit Singh; Avtar K Singh
Journal:  Restor Neurol Neurosci       Date:  2012       Impact factor: 2.406

8.  S-nitrosothiol-modified dendrimers as nitric oxide delivery vehicles.

Authors:  Nathan A Stasko; Thomas H Fischer; Mark H Schoenfisch
Journal:  Biomacromolecules       Date:  2008-02-05       Impact factor: 6.988

9.  GSNOR and ALDH2 alleviate traumatic spinal cord injury.

Authors:  Mushfiquddin Khan; Fei Qiao; S M Touhidul Islam; Tajinder S Dhammu; Pavan Kumar; Jeseong Won; Avtar K Singh; Inderjit Singh
Journal:  Brain Res       Date:  2021-02-02       Impact factor: 3.252

10.  Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact.

Authors:  Mushfiquddin Khan; Yeong-Bin Im; Anandakumar Shunmugavel; Anne G Gilg; Ramanpreet K Dhindsa; Avtar K Singh; Inderjit Singh
Journal:  J Neuroinflammation       Date:  2009-11-04       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.